US Launches Section 301 Trade Probe into Germany's Drug Pricing – Expanded to France, Spain, Italy
Key Questions
What is the US Section 301 trade probe into Germany's drug pricing?
The US has launched a Section 301 investigation challenging Germany's AMNOG and reference pricing systems, driven by pharmaceutical industry lobbying. The probe has expanded to include France, Spain, and Italy, signaling potential trade actions against EU5 pricing models.
Why has the investigation been expanded to other European countries?
Expansion follows industry pressure from companies like Pfizer and Lilly, targeting broader reference pricing practices across France, Spain, and Italy. This reflects US concerns over how European controls may affect American pharmaceutical leadership and market access.
What are the potential implications for drug pricing in Europe?
Germany's €1.9bn reform plans and ongoing pushback could reshape global pricing benchmarks and EU negotiation strategies. The probe introduces market access risks and may influence trade dynamics between the US and EU5 nations.
The US has initiated a Section 301 investigation into Germany's drug pricing system, directly challenging AMNOG and reference pricing models. The probe has now been expanded to France, Spain, and Italy, driven by pharma industry lobbying. Germany's €1.9bn reform plans and industry pushback (Pfizer, Lilly) signal real market access risk. This escalation could reshape global pricing benchmarks and trade dynamics, with immediate implications for negotiation strategies across the EU5.